drugset / Trial / NCT00151294
The Efficacy and Safety of Escitalopram for Depression in Multiple Sclerosis
Phase 4
Terminated
20 enrolled
Weill Medical College of Cornell University
Forest Laboratories · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
Emotionally labile, depressed participants with multiple sclerosis treated with escitalopram will have a greater reduction in emotional lability scores and in their psychological distress scores than those who are randomized to receive placebo.
Timeline
- Start
- 2004-11
- Primary completion
- —
- Completion
- 2006-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Escitalopram | Small molecule | 10 mg | — |